NEW YORK (GenomeWeb) – Metamark today announced that it has signed an agreement to provide its suite of urology diagnostics to 5.2 million Highmark Blue Shield members in Delaware, Pennsylvania, and West Virginia.
Cambridge, Mass.-based Metamark provides a comprehensive suite of diagnostic and prognostic tools for urology, including the Promark prostate cancer panel.
"There is increasing awareness among payers regarding the potential for new diagnostic tools to improve patient care and decrease healthcare costs," Metamark CEO Shawn Marcell said in a statement. "Metamark is at the forefront of this transformation, taking a comprehensive approach to the disease that combines our deep uropathology expertise with tests that help urologists to make more personalized treatment decisions for their patients."
Financial and other details of the agreement were not disclosed.
In December 2014 Metamark's laboratory received accreditation from theCollegeofAmerican Pathologists.